EVALUATION OF A MODIFIED BIOMATERIAL OF TYMPANOTONUS FUSCATA SHELL POWDER II: FORMULATION OF PYRIMETHAMINE AND PYRIDOXINE HYDROCHLORIDE TABLETS

  • Kenneth C Ugoeze Department of Pharmaceutics & Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, University of Port Harcourt, Nigeria
  • Amarauche Chukwu Department of Pharmaceutical Technology and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria

Abstract

A novel modified biomaterial of periwinkle shell powder, MBPSP was developed from Tympanotonus fuscata. It was assessed as a bulking agent in the formulation of pyrimethamine and pyridoxine hydrochloride tablets adopting dicalcium phosphate dihydrate (DCP) as a standard. A 100 g of the ground periwinkle shell was broken down in 166.0 ml of 2 M hydrochloric acid, clarified and treated with 5 M sodium hydroxide. The thick white precipitate obtained was washed severally and to it, ortho-phosphoric acid was dropped in bits until a thick, dehydrated bulk was attained which was dried at 60 o C and classified with 250 μm sieve. The product was coded MBPSP. Two batches of granules containing pyrimethamine (25 mg) and pyridoxine hydrochloride (50 mg) were generated by the wet granulation employing MBPSP alongside DCP. The granules were lubricated with magnesium stearate and talc and compacted into tablets at 7.55kN using a 10.50 mm diameter die and flat-faced punch fixed in a hydraulic hand press. The tablet produced were evaluated using the British Pharmacopoeia specifications. The weight variation for the pyrimethamine or pyridoxine hydrochloride tablets containing MBPSP or DCP were 0.06, 0.1, 0.097 and 0.143 % respectively. The total drug content for the individual lots of tablets for either pyrimethamine or pyridoxine hydrochloride was within 85.00-115.00 % of their label claim. Higher mechanical strength were noted for the batch of tablets manufactured with DCP and containing pyrimethamine and pyridoxine hydrochloride than MBPSP. Though the entire batches of tablets for the two drugs manufactured with either MBPSP or DCP disintegrated in less than 5.00 min with no significant difference in their individual disintegrating time (p>0.05), pyridoxine hydrochloride tablets prepared with DCP disintegrated in lesser time when compared to MBPSP (p<0.05). Only the pyrimethamine tablets prepared with MBPSP attained 75.00 % drug release in 45.00 min in line with the United States Pharmacopoeia (USP) criteria. Therefore, MBPSP could be another very useful bulking agent in the formulation of pyrimethamine immediate-release tablets by the wet granulation technique.

Keywords: Modified biomaterial, Tympanotonus fuscata, periwinkle, shell, pyrimethamine, pyridoxine hydrochloride, tablet.

 

Downloads

Download data is not yet available.

Author Biographies

Kenneth C Ugoeze, Department of Pharmaceutics & Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, University of Port Harcourt, Nigeria

Department of Pharmaceutics & Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, University of Port Harcourt, Nigeria

Amarauche Chukwu, Department of Pharmaceutical Technology and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria

Department of Pharmaceutical Technology and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria

References

1. Iannucelli V, Coppi G, Bernabei MT, Camerorni R, Air compartment multiple-unit system for prolonged gastric residence. Part-I: Formulation study. Int J Pharm., 1998; 174:47-54.
2. Avachat A and Ahire V. Characterization and evaluation of spray dried co- processed excipients and their application in solid dosage forms. Indian J Pharm Sci, 2007; 69:85-90.
3. Liebermam H.A. and Lachman L. ‘‘Tablets’’: in Pharmaceutical Dosage Forms, Vol.1, Marcel Dekker Inc.; New York, 1980.
4. Carr, R.L. ‘‘Evaluating flow properties of solids’’, Chem. Eng., 1965; 72:163 – 168.
5. Lachman L.; Lieberman H.A. & Kanig J.L. ‘‘Sustained Release Formulations’’, in: Theory and Practice of Industrial Pharmacy, 3rd ed.; Lea and Febiger, Philadelphia, 1986.
6. WHO. Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines. 15-19 October 2007. Available from: http://studylib.net/doc/9264523/guidelines---world-health-organization. Retrieved on 22nd June 2017.
7. Wade A, Weller PJ. Handbook of Pharmaceutical Excipients. 11th Ed. The Pharmaceutical Press: London, 1994; 426-8.
8. Edmund J. “Sea shells & other mollusc found on West African shores & estuaries”. In: Descriptive manual of Janet Edmund. Ghana University press, Accra, 1978; 20:100-101.
9. Ugoeze K.C, Chukwu A. Preliminary Evaluation of the Properties of Biomaterial of Tympanotonus fuscata shell as Pharmaceutical Excipient. Int. Res. J. Pharm. 2015; 6(2):104-107.
10. Ugoeze K.C, Chukwu A. Physico-chemical Properties of a Modified Biomaterial from Tympanotonus Fuscata (Periwinkle) Shell Powder Considered as Pharmaceutical Excipient. Journal of Pharmaceutical and Allied Sciences, 2017; 14(1):2417-2429.
11. Ugoeze K. C., Udeala O. K. Application of Periwinkle Shell Bio-ash (Ugoeze-bio-ash) as CO2 Donor in the Formulation of an Effervescent Low Dose Aspirin Tablet. American Journal of Biomedical Science and Engineering, 2015; 1(5): 63-70.
12. British Pharmacopeia, Her Majesty’s Stationery Office, London, 1998.
13. Shangraw R.F. Direct Compression Tabletting, Encyclopaedia of Pharmaceutical Technology, Vol.4, Marcel Dekker, U.S.A., 2nd ed., 1988; pp. 85-160.
14. Shangraw R.F. Compressed tablets by direct compression granulation in: Pharmaceutical Dosage Forms: Tablets, Vol.1, Marcel Dekker, U.S.A., 2nd ed., 1989; p. 195-246.
15. Setn B.B; Bandelin F.J. and Shangraw, R.F. Tablets in: Pharmaceutical Dosage Forms, Vol. I; Liebermann, H. and Lachman, L. (eds.), Marcel Dekker Inc, New York, 1980; p.110.
16. Marks A.M. & Sciarra J.J. Effects of size and other physical properties of granules and their corresponding tablets, J. Pharm. Sci. 1968; 57: 497.
17. Parrot, E.L. Pharmaceutical Technology; Fundamental Pharmaceutics, Burges Pub. Co., Minneapolis, 1970; pp. 17-18, 74.
18. Lazarus J. and Lachman L. Experiences in development of directly compressible tablets containing potassium chloride, J. Pharm. Sci. 1966; 55:1121.
19. Rasenack N. and Muller B.W. Crystal habit and tableting behaviour, Int. J. Pharm. 2002; 244:45-57.
20. Sherringtonn P.J.; Oliver R. Granulation: in: Encyclopaedia of Pharmaceutical Technology, Vol. 3, 2nd Edition, Edited by James Swarbrick and James C. Boylan, Marcel Dekker, Inc. New York, 1981; pp. 2713-2731.
21. Ejiofor O; Esezobo S, Pilpel N. The plasto-elasticity and compressibility of coated powders and the tensile strength of their tablets, J. Pharm. Pharmac. 1986; 38(1):1-7.
22. The United States Pharmacopoeia, U.S.P, NF. The United States Pharmacopoeial Convention, Rockville, 2007.
Statistics
282 Views | 143 Downloads
How to Cite
1.
Ugoeze K, Chukwu A. EVALUATION OF A MODIFIED BIOMATERIAL OF TYMPANOTONUS FUSCATA SHELL POWDER II: FORMULATION OF PYRIMETHAMINE AND PYRIDOXINE HYDROCHLORIDE TABLETS. JDDT [Internet]. 22Apr.2018 [cited 30Oct.2020];8(2):188-93. Available from: http://www.jddtonline.info/index.php/jddt/article/view/1709